NMDA receptors antiepileptics

Kohl B. K. and Dannhardt G. (2001). The NMDA receptor complex a promising target for novel antiepileptic strategies. Curr. Med. Chem. 8 1275-1289. 

Figure 6.8. Possible sites of interaction of antiepileptic drugs on glutamate-mediatedtransmission (after Ref 174). The NMDA receptor is associated with an ion channel permeable to Na" and and is associated with a number of modulatory sites, including a strychnine-insensitive glycinebinding site. Glycine is an absolute requirement for the receptor-channel complex to enter the open state.

Conantokin-G (Con-G), a 17-residue linear conopeptide that contains five 7-carboxyglutamate (Gla) residues, is an antagonist of the NMDA receptor. Conantokin-G has been shown to be an effective antiepileptic agent in several animal models of seizure. ... 

Topiramate also antagonizes the effects of glutamate at non-N-methyl-o-aspartate (non-NMDA) receptors, and it also inhibits certain isoenzymes of carbonic anhydrase, although this effect may not be a major feature of its antiepileptic/mood-stabilizing activity. 

APV (2-amino-5-phosphonopentanoic acid) is a competitive (NMDA) GLUTAMATE RECEPTOR ANTAGONIST which has anticonvulsant/antiepileptic actions. It is used as a pharmacological tool. 

---